Defining the Ideal Cranial Vault Height Ratio Via Morphometric Analysis: A Preliminary Study
Listen to this summary
The authors aimed to determine the optimal cranial vault height ratio (CVHR) in Chinese women through morphometric and perceptual analyses. Their study found that a CVHR of 0.60 to 0.65 was perceived as most attractive, with variations in preference noted between general respondents and aesthetic practitioners. This research provides a preliminary quantitative reference for aesthetic cranial contouring procedures.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
View all →Jun 9, 2026 · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Novel 1550-nm Nonablative Resurfacing Laser With Focal Point Technology Improves Fine Lines and Wrinkles With High Energy Delivery
Jun 3, 2026 · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Lasers and Acquired Melanocytic Nevi: A Systematic Review
More in Dermatology
View all →Nov 19, 2026 · Lancet (London, England)
Spontaneous coronary artery dissection: implications for women's health, clinical care, and future research.
Nov 19, 2026 · Lancet (London, England)
Reproductive health in women in Britain from 2010 to 2024: findings from repeated, cross-sectional National Surveys of Sexual Attitudes and Lifestyles (Natsal).
Nov 19, 2026 · Lancet (London, England)
Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.
Nov 19, 2026 · The New England journal of medicine
Assessing Multiple Treatment Regimens for Tuberculosis.
Nov 18, 2026 · The New England journal of medicine
Acute Respiratory Distress Syndrome.
Nov 17, 2026 · Lancet (London, England)
Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


